Cargando…
Safety of Infliximab for the Eye Under Human T-Cell Leukemia Virus Type 1 Infectious Conditions in vitro
Use of biologics has been widely advocated for inflammatory diseases recently. Anti-tumor necrosis factor (TNF)-α antibody therapy is reportedly effective against ocular inflammation. However, side effects of TNF-α inhibition have been reported, particularly in the form of exacerbation of infections...
Autores principales: | Uchida, Minami, Kamoi, Koju, Ando, Naoko, Wei, Chenxi, Karube, Hisako, Ohno-Matsui, Kyoko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759608/ https://www.ncbi.nlm.nih.gov/pubmed/31620105 http://dx.doi.org/10.3389/fmicb.2019.02148 |
Ejemplares similares
-
In vitro Evaluation of the Safety of Adalimumab for the Eye Under HTLV-1 Infection Status: A Preliminary Study
por: Kurozumi-Karube, Hisako, et al.
Publicado: (2020) -
Mechanism of Secondary Glaucoma Development in HTLV-1 Uveitis
por: Zong, Yuan, et al.
Publicado: (2022) -
Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet’s disease
por: Karube, Hisako, et al.
Publicado: (2016) -
A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome
por: Horiguchi, Noe, et al.
Publicado: (2020) -
Safety of intraocular anti-VEGF antibody treatment under in vitro HTLV-1 infection
por: Zong, Yuan, et al.
Publicado: (2023)